Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Amyris Stock Rose as Much as 12.2% Today

By Maxx Chatsko – Jul 27, 2020 at 11:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The synthetic biology pioneer announced a collaboration for its vaccine adjuvant ambitions.

What happened

Shares of Amyris (AMRS -5.59%) gained over 12% today after the company announced it had signed a binding term sheet with the Infectious Disease Research Institute (IDRI) to collaborate on a SARS-CoV-2 vaccine candidate. 

Specifically, IDRI will develop a vaccine candidate based on its RNA vaccine platform, while Amyris will supply squalene for use in the vaccine adjuvant. Several seasonal influenza vaccines administered to adults over the age of 65 have included squalene-containing adjuvants, which help to boost the body's immune response to the vaccine. The idea is that adjuvants will become a useful component of SARS-CoV-2 vaccines, too. 

As of 12:09 p.m. EDT, the small-cap stock had settled to a 5.2% gain.

An arrow bouncing up shelves on a wall.

Image source: Getty Images.

So what

Squalene is commonly harvested from blue shark livers and olives, although the extraction processes are inefficient and prone to market risks. For example, there are ethical concerns regarding commercial shark fishing, and some of the planet's most productive olive-producing regions have faced increasing pressure from pests in the last decade.

Amyris has genetically engineered yeast to manufacture farnesene through fermentation. Two farnesene molecules can then be combined to form one squalene molecule. Bioprocesses can be scaled more easily than shark- or olive-based harvesting methods, require a significantly smaller footprint, and can be lower cost. The company has manufactured farnesene and its derivatives for various uses over the years, including transportation fuels (farnesane) and cosmetics (squalane). 

It's possible adjuvants will be added to SARS-CoV-2 vaccines administered to people of any age. However, squalene-based adjuvants are typically only included in vaccines administered to those 65 years and older, which represents a relatively small market size. Amyris is jumping on the coronavirus pandemic bandwagon nonetheless.

Now what

Amyris has touted its ability to manufacture various products and opportunistically jumped into many markets in the last two decades. But past efforts to commercialize transportation fuels, performance polymers, lubricants, flavors, fragrances, vitamins, cannabinoids, sweetener ingredients, and others haven't panned out or were sold off to keep the lights on. The business has never posted consistent profits. 

Could a squalene-based adjuvant be different? Perhaps. However, Amyris doesn't own a manufacturing facility and it's not clear if the company's farnesene manufacturing process is approved by the U.S. Food and Drug Administration (FDA), which would be required for a squalene-based adjuvant. Therefore, individual investors need to weigh whether the signing of a binding term sheet is a noteworthy event or just another public statement from a company with a long history of overpromising and underdelivering.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amyris, Inc. Stock Quote
Amyris, Inc.
AMRS
$3.04 (-5.59%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.